Search in the Abstract Database

Abstracts Search 2019

P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies

S. Danese*1, B. E. Sands2, R. W. Leong3,4, H. Zhang5, J. Johanns5, P. Szapary5, C. Marano5, C. Han6

1Humanitas Research Hospital, Milan, Italy, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Concord Hospital, Sydney, Australia, 4Macquarie University Hospital, Sydney, Australia, 5Janssen Research and Development, LLC, Spring House, USA, 6Janssen Global Services, LLC, Malvern, USA


The UNIFI studies evaluated the safety and efficacy of ustekinumab (UST) intravenous (IV) induction and subcutaneous (SC) maintenance in patients with moderately to severely active ulcerative colitis (UC). We evaluated patient-reported outcomes related to general health status in these studies.


In the induction study, eligible patients were randomised to a single IV dose of placebo (PBO, n = 319), UST 130 mg (n = 320), or UST ~6 mg/kg (n = 322). Patients who were in clinical response 8 weeks after receiving UST induction were eligible for the maintenance study and were randomised to SC PBO (n = 175), UST 90 mg q12w (n = 172), or UST 90 mg q8w (n = 176). General health status was assessed using the 36-item Short Form Health Survey (SF-36) and the visual analogue scale of EuroQoL-5D Health Questionnaire (EQ VAS). SF-36 measured 8 functional areas that were summarised into physical and mental component summary scores (PCS and MCS). EQ VAS ranges from 0 to 100. Higher SF-36 and EQ VAS scores indicate better health status.


At baseline of the induction study, mean SF-36 PCS and MCS scores were below the USA general population norm of 50 and indicative of patients with significantly impaired general health status (Table 1).

Table 1. Patient-reported outcomes related to general health status at Week 8 in patients who received IV induction treatment with ustekinumab or placebo.

Eight weeks after IV induction, patients receiving UST reported significantly greater improvements in mean SF-36 PCS and MCS and EQ VAS scores compared with PBO (p < 0.001). Statistically significant differences between UST and PBO were observed for each of the individual subscales of the SF-36 (p ≤ 0.002). Through Week 44 of the maintenance study, mean SF-36 PCS scores worsened in the PBO group, were maintained in the UST q12w group, and improved in the UST q8w group (Table 2).

Abstract P406 – Table 2. Patient-reported outcomes related to general health status at Week 44 in patients who responded to ustekinumab induction and received SC maintenance treatment with ustekinumab or placebo.

Mean SF-36 MCS also worsened in the PBO group and were maintained in the UST q12w and q8w groups (p ≤ 0.009). The proportions of patients with clinically meaningful improvements in SF-36 PCS and MCS (≥5 points) and EQ VAS ( >10 points) from induction baseline to maintenance Week 44 were significantly greater in the UST groups compared with PBO (p ≤ 0.001).


Patients reported significantly greater improvements in general health status after UST IV induction compared with PBO. In patients who responded to UST IV induction, improvements were sustained or increased with 44 weeks of SC UST maintenance therapy.